A new tool to predict how well patients with advanced lung cancer will respond to immunotherapy
RadIO: A Novel Radiomics Toolkit to Predict and Characterize Response to Immunotherapy in Stage III Non-Small Cell Lung Cancer
['FUNDING_OTHER'] · VETERANS HEALTH ADMINISTRATION · NIH-10951494
This study is testing a new tool that uses advanced imaging and artificial intelligence to help doctors figure out which veterans with Stage III non-small cell lung cancer are most likely to benefit from immunotherapy after their initial treatment, so they can get the best care possible and avoid unnecessary treatments.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VETERANS HEALTH ADMINISTRATION (nih funded) |
| Locations | 1 site (Decatur, UNITED STATES) |
| Trial ID | NIH-10951494 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel radiomics toolkit called RadIO, which uses advanced imaging techniques to analyze tumor characteristics in patients with Stage III non-small cell lung cancer (NSCLC). By leveraging artificial intelligence, the toolkit aims to predict which patients are likely to benefit from immunotherapy following chemoradiation treatment. The goal is to enhance patient care by identifying those who will respond positively to treatment, thereby reducing unnecessary trips for ineffective therapies and improving overall quality of life for veterans. The research involves analyzing imaging data and clinical outcomes to refine treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates for this research are veterans diagnosed with Stage III unresectable non-small cell lung cancer who are considering immunotherapy after chemoradiation.
Not a fit: Patients with early-stage lung cancer or those who are not veterans may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for patients with advanced lung cancer, ensuring that only those who will benefit from immunotherapy receive it.
How similar studies have performed: Other research has shown promise in using imaging and AI to predict treatment responses in cancer, suggesting that this approach could be effective.
Where this research is happening
Decatur, UNITED STATES
- VETERANS HEALTH ADMINISTRATION — Decatur, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MADABHUSHI, ANANT — VETERANS HEALTH ADMINISTRATION
- Study coordinator: MADABHUSHI, ANANT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy